Related Experiment Videos
Monoclonal antibody specific for an activated RAS protein
Summary
A new monoclonal antibody, DWP, specifically detects activated RAS proteins with Val or Cys at position 12 in cancer cells. This antibody shows promise for identifying RAS mutations in human neoplasms.
Area of Science:
- Oncology
- Molecular Biology
- Immunology
Background:
- Activated RAS genes, mutated at positions 12, 13, or 61, are found in 10-20% of human neoplasms.
- RAS proteins (p21s) with specific amino acid substitutions drive cellular transformation and cancer development.
Purpose of the Study:
- To develop and characterize a monoclonal antibody (DWP) for detecting activated RAS proteins.
- To assess the specificity and utility of DWP in identifying RAS mutations in cancer cells and tissues.
Main Methods:
- Generation of a monoclonal antibody (DWP) against a synthetic peptide of mutated RAS.
- Competition assays, immunoblot analysis, and immunohistochemical studies were used to evaluate DWP's reactivity.
- Analysis of transformed cell lines and primary human carcinoma specimens.
Main Results:
- DWP specifically binds to RAS proteins with Val or Cys at position 12, not normal RAS or other mutations.
- Immunohistochemical studies confirmed DWP's preferential binding to human carcinoma cells.
- DWP staining in formalin-fixed primary tumors did not always correlate with molecular detection of RAS mutations.
Conclusions:
- The DWP antibody is a specific tool for detecting certain activated RAS mutations (Val/Cys at position 12) in cancer research.
- DWP shows potential for identifying RAS-mutated cancer cells, though further validation is needed for clinical application in primary specimens.